TY  -  
T1  - Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro 
SN  -  /  
UR  - http://hdl.handle.net/10138/335997 
T3  -  
A1  - Brunotte, Linda; Zheng, Shuyu; Mecate-Zambrano, Angeles; Tang, Jing; Ludwig, Stephan; Rescher, Ursula; Schloer, Sebastian 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - The ongoing SARS-CoV-2 pandemic requires efficient and safe antiviral treatment strategies. Drug repurposing represents a fast and low-cost approach to the development of new medical treatment options. The direct antiviral agent remdesivir has been reported to exert antiviral activity against SARS-CoV-2. Whereas remdesivir only has a very short half-life time and a bioactivation, which relies on pro-drug activating enzymes, its plasma metabolite GS-441524 can be activated through various kinases... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - EBOLA; FUNCTIONAL INHIBITORS; GS-5734; HOST-DIRECTED THERAPIES; MORTALITY; PRODRUG; SARS-CoV-2; VIRUS; combination therapy; fluoxetine; nucleoside GS-441524; synergy; 317 Pharmacy 
N1  -   
PP  -  
ER  -